

**PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program  
Measure Crosswalk by Measure Type for Program Years FY 2016 to FY 2023**

NQF #	PCH #	Measures Grouped by Measure Topic	Chart-Abstracted	Claims-Based	Program Year							
					FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023
<b>Clinical Process/Cancer-Specific Treatment</b>												
#0223	PCH-1	Adjuvant Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis to Patients Under the Age of 80 with AJCC III (lymph node positive) Colon Cancer	✓		✓	✓	✓	N/A	N/A	N/A	N/A	N/A
#0559	PCH-2	Combination Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis for Women Under 70 with AJCC T1cN0M0, or Stage IB—III Hormone Receptor Negative Breast Cancer	✓		✓	✓	✓	N/A	N/A	N/A	N/A	N/A
#0220	PCH-3	Adjuvant Hormonal Therapy	✓		✓	✓	✓	N/A	N/A	N/A	N/A	N/A
<b>Safety and Healthcare-Associated Infection</b>												
#0139	PCH-4	NHSN Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure	✓		✓	✓	✓	✓	✓	✓	✓	✓

**PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program  
Measure Crosswalk by Measure Type for Program Years FY 2016 to FY 2023**

NQF #	PCH #	Measures Grouped by Measure Topic	Chart-Abstracted	Claims-Based	Program Year							
					FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023
#0138	PCH-5	NHSN Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure	✓		✓	✓	✓	✓	✓	✓	✓	✓
#0753	PCH-6* PCH-7*	ACS–CDC Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure	✓		✓§	✓	✓	✓	✓	✓	✓	✓
#1717	PCH-26	NHSN Facility-wide Inpatient Hospital-onset <i>Clostridium difficile</i> Infection (CDI) Outcome Measure	✓		N/A	N/A	✓	✓	✓	✓	✓	✓
#1716	PCH-27	NHSN Facility-wide Inpatient Hospital-onset Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) Bacteremia Outcome Measure	✓		N/A	N/A	✓	✓	✓	✓	✓	✓
#0431	PCH-28	NHSN Influenza Vaccination Coverage Among Healthcare Personnel (HCP)	✓		N/A	N/A	✓	✓	✓	✓	✓	✓

**PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program  
Measure Crosswalk by Measure Type for Program Years FY 2016 to FY 2023**

NQF #	PCH #	Measures Grouped by Measure Topic	Chart-Abstracted	Claims-Based	Program Year							
					FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023
<b>Clinical Process/Oncology Care Measures</b>												
#0382	PCH-14	Oncology: Radiation Dose Limits to Normal Tissues	✓		✓†	✓§	✓	✓	✓	N/A	N/A	N/A
#0383	PCH-15	Oncology: Medical and Radiation—Plan of Care for Moderate to Severe Pain	✓		✓†	✓§	✓	✓	✓	✓	✓	✓
#0384	PCH-16	Oncology: Medical and Radiation—Pain Intensity Quantified	✓		✓†	✓§	✓	✓	✓	N/A	N/A	N/A
#0390	PCH-17	Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk Prostate Cancer Patients	✓		✓†	✓§	✓	✓	✓	N/A	N/A	N/A
#0389	PCH-18	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	✓		✓†	✓§	✓	✓	✓	N/A	N/A	N/A
#0210	PCH-32	Proportion of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life		✓	N/A	N/A	N/A	N/A	N/A**	N/A	✓	✓

**PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program  
Measure Crosswalk by Measure Type for Program Years FY 2016 to FY 2023**

NQF #	PCH #	Measures Grouped by Measure Topic	Chart-Abstracted	Claims-Based	Program Year								
					FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	
#0215	PCH-34	Proportion of Patients Who Died from Cancer Not Admitted to Hospice		✓	N/A	N/A	N/A	N/A	N/A	N/A**	N/A	✓	✓
<b>Intermediate Clinical Outcome Measures</b>													
#0213	PCH-33	Proportion of Patients Who Died from Cancer Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life		✓	N/A	N/A	N/A	N/A	N/A	N/A**	N/A	✓	✓
#0216	PCH-35	Proportion of Patients Who Died from Cancer Admitted to Hospice for Less Than Three Days		✓	N/A	N/A	N/A	N/A	N/A	N/A**	N/A	✓	✓
<b>Surgical Care Improvement Project (SCIP)</b>													
#0218	PCH-19	SCIP-VTE-2 Surgery Patients Who Received Appropriate Venous Thromboembolism Prophylaxis Within 24 Hours Prior to Surgery to 24 Hours After Surgery	✓		✓ <sup>†</sup>	✓ <sup>‡</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A
#0453	PCH-20	SCIP-Inf-9 Urinary Catheter Removed on Postoperative Day 1 (POD1) or Postoperative Day 2 (POD2) with Day of Surgery Being Day Zero	✓		✓ <sup>†</sup>	✓ <sup>‡</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A

**PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program  
Measure Crosswalk by Measure Type for Program Years FY 2016 to FY 2023**

NQF #	PCH #	Measures Grouped by Measure Topic	Chart-Abstracted	Claims-Based	Program Year							
					FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023
#0527	PCH-21	SCIP-Inf-1 Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision	✓		✓†	✓‡	N/A	N/A	N/A	N/A	N/A	N/A
#0528	PCH-22	SCIP-Inf-2 Prophylactic Antibiotic Selection for Surgical Patients	✓		✓†	✓‡	N/A	N/A	N/A	N/A	N/A	N/A
#0529	PCH-23	SCIP-Inf-3 Prophylactic Antibiotics Discontinued Within 24 Hours After Surgery End Time	✓		✓†	✓‡	N/A	N/A	N/A	N/A	N/A	N/A
#0284	PCH-24	SCIP-Card-2 Surgery Patients on Beta-Blocker Therapy Prior to Arrival Who Received a Beta-Blocker During the Perioperative Period	✓		✓†	✓‡	N/A	N/A	N/A	N/A	N/A	N/A
<b>Clinical Effectiveness Measure</b>												
N/A	PCH-25 <sup>W</sup>	External Beam Radiotherapy (EBRT) for Bone Metastases	✓		N/A	✓	✓	✓	✓	✓	N/A	N/A
<b>Patient Engagement/Experience of Care</b>												
#0166	PCH-29	Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey	✓		✓§	✓	✓	✓	✓	✓	✓	✓

## PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program Measure Crosswalk by Measure Type for Program Years FY 2016 to FY 2023

NQF #	PCH #	Measures Grouped by Measure Topic	Chart-Abstracted	Claims-Based	Program Year							
					FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023
<b>Claims-Based Outcome Measures</b>												
N/A	PCH-30 <sup>†</sup> PCH-31 <sup>†</sup>	Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy		✓	N/A	N/A	N/A	✓	✓	✓	✓	✓
3188	PCH-36	30-Day Unplanned Readmissions for Cancer Patients		✓	N/A	N/A	N/A	N/A	N/A	N/A <sup>^</sup>	✓	✓
N/A	PCH-37	Surgical Treatment Complications for Localized Prostate Cancer		✓	N/A	N/A	N/A	N/A	N/A	N/A	✓	✓

<b>ACS-CDC</b>	American College of Surgeons-Centers for Disease Control and Prevention	<b>N/A</b>	Not applicable for stated program year
<b>AJCC</b>	Adjuvant Chemotherapy Considered	<b>NHSN</b>	National Healthcare Safety Network
<b>FY</b>	Fiscal Year	<b>NQF</b>	National Quality Forum
<b>IPPS</b>	Inpatient Prospective Payment System	<b>PCH</b>	PPS-Exempt Cancer Hospital
<b>LTCH</b>	Long-Term Care Hospital	<b>PPS</b>	Prospective Payment System

✓=Applicable for stated program year

\* While NQF #0753 is a single harmonized measure containing SSI data for both colon and abdominal hysterectomies, the data are reported specific to each surgery on the PPS-Exempt Cancer Hospital Report; therefore, it has two PCH numbers, PCH-6 (SSI-colon) and PCH-7 (SSI-hysterectomy).

\*\* Although finalized for the inclusion in the PCHQR Program in the FY 2018 IPPS/LTCH PPS Final Rule (82 FR 38414) for FY 2020 program year, the FY 2020 IPPS/LTCH PPS Final Rule (84 FR 42524) specified the first confidential national reporting period as 07/01/2019–06/30/2020, which aligns with the FY 2022 program year.

<sup>^</sup> Although finalized for inclusion in the PCHQR Program in the FY 2019 IPPS/LTCH PPS Final Rule (83 FR 41613) for the FY 2021 program year, the FY 2020 IPPS/LTCH PPS Final Rule (84 FR 42524) specified the first confidential national reporting period as 10/01/2019 – 09/30/2020, which aligns with the FY 2022 program year. § Quarters 2–4 apply to the Fiscal Year.

<sup>†</sup> Measure finalized for removal from the PCHQR Program in the FY 2020 IPPS/LTCH PPS Final Rule, beginning FY 2022 Program Year and subsequent years.

<sup>‡</sup> Only Quarter 1 applies to Fiscal Year 2016.

<sup>§</sup> Only Quarters 2 and 3 apply to this Fiscal Year.

<sup>¶</sup> While PCH-30 and PCH-31 are part of a single measure, Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy, there are two rates reported. PCH-30 is the risk-standardized admission rate (RSAR), and PCH-31 is the risk-standardized ED visit rate (RSEDR).